亿帆医药：重酒石酸去甲肾上腺素注射用浓溶液获新加坡注册批文

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - YiFan Pharmaceutical's wholly-owned subsidiary, SciGen Pte. Ltd., has been granted a market registration approval by HSA [1] - The approved product, racemic norepinephrine injection solution, is used for blood pressure control in adults experiencing severe acute hypotension [1] - The drug is designed to elevate blood pressure levels in critical situations [1]